|
KMID : 0360220150560060847
|
|
Journal of the Korean Ophthalmological Society
2015 Volume.56 No. 6 p.847 ~ p.855
|
|
|
The Effect of Subconjunctival Bevacizumab Injection before Conjunctival Autograft for Pterygium
|
|
Kim Yong-Il
Lee Geun-Young
Kim Eun-Joo
Kim Yeoun-Hee
Lee Kyoo-Won
Park Young-Jeung
|
|
|
Abstract
|
|
|
Purpose: To evaluate the effect of subconjunctival bevacizumab injection before conjunctival autograft for pterygium.
Methods: Twenty-five eyes (25 patients) with pterygium received a subconjunctival injection of 2.5 mg (0.1 mL) bevacizumab 1-2 weeks prior to conjunctival autograft surgery. The control group (25 eyes of 25 patients) received the same operation. Two weeks, 1 month and every month after the surgery, the vascularization of surgical site, the recurrence rate and the effect of wound healing were analyzed.
Results: The bevacizumab group showed a decreased conjunctival vascularity grade compared with the control group based on light microscopy. The bevacizumab group also showed lower vascular epithelial growth factor (VEGF) compared with the control group using immunohistochemical analysis and western blot. There was no recurrence in both groups, but, persistent autograft edema was observed at 8 weeks postoperatively in the bevacizumab group.
Conclusions: Although preoperative injection of bevacizumab effectively reduced vascularity and VEGF concentration of pterygium tissue, prolonged autograft edema was observed. Based on these results, bevacizumab inhibits lymphangiogenesis as well as angiogenesis. Therefore, delayed wound healing should be considered when subconjunctival bevacizumab injection is administered before pterygium surgery.
|
|
|
KEYWORD
|
|
|
Bevacizumab, Conjunctival autograft, Lymphangiogenesis, Pterygium, VEGF
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|